Zoledronic acid to prevent bone loss from HIV treatment
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This trial tests if zoledronic acid, a drug that strengthens bones, can prevent bone loss caused by starting HIV treatment. It is for people newly diagnosed with HIV who have not yet taken any HIV medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Diagnosed with HIV
- Never taken medication to prevent or treat HIV
- Not pregnant, breastfeeding, or planning to become pregnant
- No history of severe reaction to bisphosphonate drugs (like severe jaw bone problems or unusual thigh breaks)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how the drug zoledronic acid (used for bone loss) works in people with kidney disease who are on dialysis. It aims to help treat osteoporosis (weak bones) safely in this group.
This study tests whether zoledronic acid, a medicine given by IV, helps prevent bone problems in women with breast cancer that has spread to the bones. It looks at how well the drug works in a real-world setting to reduce the risk of fractures or other bone issues.
This trial tests if a bone-strengthening drug called zoledronic acid can help people with congenital dyserythropoietic anemia (CDA), a rare type of anemia. It's for adults with moderate to severe anemia who may also need blood transfusions.
This study tests if alendronate, a bone-strengthening medicine, can shrink the reservoir of HIV that stays in your body even when on treatment. You must have well-controlled HIV on antiretroviral therapy for at least one year but no more than ten years, and meet specific health requirements.
This Phase 2 study tests whether zoledronic acid or denosumab can prevent bone thinning in critically ill adults after staying in the ICU. It may help reduce the risk of future bone fractures if your body is at higher risk during and after critical illness.
This study compares two treatment plans for women with osteoporosis to see which one improves hip bone density more. Participants will either get two medications in sequence (romosozumab followed by denosumab) or one medication (zoledronic acid), both given as injections or infusions. The goal is to find a treatment that reduces fracture risk.
Hear when a new HIV Infected Individuals trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.